---
document_datetime: 2023-11-24 15:26:59
document_pages: 9
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/spectrila-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: spectrila-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 5.5292131
conversion_datetime: 2025-12-31 05:26:47.912792
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Spectrila

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0034/G            | This was an application for a group of variations. B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation B.II.g.4.b - Changes to an approved change management protocol - Minor changes that do not | 20/06/2023                          | n/a                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | change the strategy defined in the protocol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |     |             |                                                                                             |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|---------------------------------------------------------------------------------------------|
| II/0032/G | This was an application for a group of variations. C.I.4: Update of sections 4.4 and 4.6 of the SmPC in order to include the recommendations from the SWP regarding genotoxic medicinal products and contraception duration period; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI. C.I.6.b: Deletion of the indication lymphoblastic lymphoma (LBL) in section 5.3 of the SmPC, as Spectrila is not approved for LBL. C.I.6.b - Change(s) to therapeutic indication(s) - Deletion of a therapeutic indication C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 09/03/2023 |     | SmPC and PL | SmPC new text For more information, please refer to the Summary of Product Characteristics. |
| IB/0033/G | This was an application for a group of variations. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other variation                                                                                                                                                                                                                                                                                                                                                                                                            | 08/12/2022 | n/a |             |                                                                                             |

<div style=\"page-break-after: always\"></div>

| II/0029   | B.I.e.2 - Introduction of a post approval change management protocol related to the AS                                                                                                                                             | 08/12/2022   | n/a   |               |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|---------------|
| II/0031   | B.II.g.2 - Introduction of a post approval change management protocol related to the finished product                                                                                                                              | 01/09/2022   | n/a   |               |
| IB/0030   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                      | 26/04/2022   | n/a   |               |
| II/0026   | B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a | 24/03/2022   | n/a   | biological AS |
| IB/0028   | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                               | 06/01/2022   | n/a   |               |
| IA/0027   | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                   | 19/11/2021   | n/a   |               |
| II/0025   | B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a | 02/09/2021   | n/a   |               |

<div style=\"page-break-after: always\"></div>

|                     | biological AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |            |     |                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/10445 /202101 | Periodic Safety Update EU Single assessment - asparaginase (centrally authorised product)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 02/09/2021 | n/a | PRAC Recommendation - maintenance |
| IA/0023/G           | This was an application for a group of variations. B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                     | 07/01/2021 | n/a |                                   |
| II/0021/G           | This was an application for a group of variations. B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch | 10/12/2020 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|                     | product and any of the test methods at the site is a biol/immunol method B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation                                                                                                                                                                      |            |            |                        |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| IA/0022             | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                             | 30/11/2020 | n/a        |                        |                                   |
| R/0018              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                  | 23/07/2020 | 24/09/2020 | SmPC, Labelling and PL |                                   |
| PSUSA/10445 /202001 | Periodic Safety Update EU Single assessment - asparaginase (centrally authorised product)                                                                                                                                                                                                                                                                                | 04/09/2020 | n/a        |                        | PRAC Recommendation - maintenance |
| IB/0020             | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                               | 15/07/2020 | n/a        |                        |                                   |
| II/0017             | Update of the Risk Management Plan (version 12) for Spectrila in accordance with GVP Module V Rev 2 including the implementation of the new RMP template and the new definition of safety concerns. The QPPV and the Milestones / Timelines for the clinical study MC-Spectrila.1/ALL were updated in accordance to the newly applied DLP for this Risk Management Plan. | 14/05/2020 | n/a        |                        |                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |     |          |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------|
| II/0015/G | This was an application for a group of variations. B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished product - Deletion of a non-significant in-process test B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.e.1.z - Change in immediate packaging of the | 05/03/2020 | n/a | finished |

<div style=\"page-break-after: always\"></div>

| IA/0016             | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                                                                                                                                                                    | 18/12/2019   | n/a        |             |                                                                                                                                            |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10445 /201901 | Periodic Safety Update EU Single assessment - asparaginase (centrally authorised product)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 11/07/2019   | n/a        |             | PRAC Recommendation - maintenance                                                                                                          |
| IB/0014             | B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                      | 05/06/2019   | n/a        |             |                                                                                                                                            |
| PSUSA/10445 /201807 | Periodic Safety Update EU Single assessment - asparaginase (centrally authorised product)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 28/02/2019   | 26/04/2019 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10445/201807. |
| IB/0012/G           | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a | 04/01/2019   | n/a        |             |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|                     | Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place   |            |            |                    |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|--------------------|-----------------------------------|
| IB/0009             | B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 13/08/2018 | n/a        |                    |                                   |
| PSUSA/10445 /201801 | Periodic Safety Update EU Single assessment - asparaginase (centrally authorised product)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 12/07/2018 | n/a        |                    | PRAC Recommendation - maintenance |
| IB/0008             | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 18/06/2018 | 26/04/2019 | SmPC and Labelling |                                   |
| PSUSA/10445 /201707 | Periodic Safety Update EU Single assessment - asparaginase (centrally authorised product)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 08/02/2018 | n/a        |                    | PRAC Recommendation - maintenance |
| IA/0006             | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 19/12/2017 | n/a        |                    |                                   |

<div style=\"page-break-after: always\"></div>

|                     | finished product, including quality control sites (excluding manufacturer for batch release)                                              |            |            |      |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-----------------------------------|
| PSUSA/10445 /201701 | Periodic Safety Update EU Single assessment - asparaginase (centrally authorised product)                                                 | 01/09/2017 | n/a        |      | PRAC Recommendation - maintenance |
| IB/0003             | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) | 20/07/2017 | 29/06/2018 | SmPC |                                   |
| PSUSA/10445 /201607 | Periodic Safety Update EU Single assessment - asparaginase (centrally authorised product)                                                 | 09/02/2017 | n/a        |      | PRAC Recommendation - maintenance |